Skip to main content
Clinical Trials/NCT06231264
NCT06231264
Recruiting
N/A

A Multicenter Randomized Controlled Trial of Transcutaneous Electrical Acustimulation in the Treatment of Mild to Moderate Ulcerative Colitis

Xijing Hospital4 sites in 1 country96 target enrollmentJanuary 19, 2024

Overview

Phase
N/A
Intervention
Not specified
Conditions
Ulcerative Colitis
Sponsor
Xijing Hospital
Enrollment
96
Locations
4
Primary Endpoint
Clinical response
Status
Recruiting
Last Updated
11 months ago

Overview

Brief Summary

The aim of this study was to evaluate the efficacy and safety of transcutaneous electrical acustimulation in patients with mild to moderate ulcerative colitis.

Registry
clinicaltrials.gov
Start Date
January 19, 2024
End Date
May 1, 2026
Last Updated
11 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Xijing Hospital
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age ≥18 years
  • Ulcerative colitis diagnosed for at least 3 mouths.
  • Mayo score 4-10, Mayo endoscopic score 2-3 points
  • Resistant to at least one type of medical treatments

Exclusion Criteria

  • Treatment-naive ulcerative colitis (no previous treatment)
  • Acute severe ulcerative colitis
  • Previous surgical treatment or severe colitis at imminent risk of surgery infective colitis
  • Other systemic diseases
  • Pregnancy and lactation
  • Allergic to the electrode patch

Outcomes

Primary Outcomes

Clinical response

Time Frame: 8 weeks

decrease of ≥3 points and ≥30% from baseline mayo score and decrease of ≥1 point in rectal bleeding subscore or absolute rectal bleeding subscore ≤ 1

Secondary Outcomes

  • Endoscopic remission(8 weeks)
  • Fecal calprotectin(4 and 8 weeks)
  • C reactive protein(4 and 8 weeks)
  • pancreatic polypeptide(4 and 8 weeks)
  • Change from baseline in the Mayo score(8 weeks)
  • norepinephrine(4 and 8 weeks)
  • Hospital Anxiety and Depression scale score(4 and 8 weeks)
  • Clinical remission(8 weeks)
  • erythrocyte sedimentation rate(4 and 8 weeks)
  • Symptomatic remission(2, 4, 6, and 8 weeks)
  • acetyl choline(8 weeks)
  • Inflammatory Bowel Disease Questionnaire Score(4 and 8 weeks)
  • Pittsburgh sleep quality index(4 and 8 weeks)
  • alpha7 nicotinic acetylcholine receptor(8 weeks)
  • autonomic profile characteristics(4 and 8 weeks)

Study Sites (4)

Loading locations...

Similar Trials